<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13454">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396136</url>
  </required_header>
  <id_info>
    <org_study_id>20061550</org_study_id>
    <nct_id>NCT00396136</nct_id>
  </id_info>
  <brief_title>COSMO Post Approval Registry: Corox OTW Steroid LV Lead Monitoring</brief_title>
  <official_title>Corox OTW Steroid LV Lead Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this post approval registry is to confirm the long-term safety and
      effectiveness of the Corox Over-the-wire (OTW) Steroid Left Ventricular (LV) lead as used in
      conjunction with a BIOTRONK cardiac resynchronization therapy defibrillator (CRT-D). The
      Corox OTW Steroid LV Lead is capable of providing permanent pacing therapy to the left
      ventricle in a CRT-D system. The following are the specific objectives to be evaluated
      during this post-approval registry:

        -  Long-term effectiveness of the COROX OTW Steroid in providing biventricular pacing

        -  Safety of the COROX OTW Steroid LV pacing lead
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This post approval registry enrolled 221 patients from 34 centers. The collection of
      registry data continued for three years for each enrolled subject. Potential patients were
      screened by the enrolling physician according to the detailed inclusion and exclusion
      criteria below.

      The specific required visits for this registry are: Enrollment, Three-month, Six month,
      One-year, Routine Follow-Ups (every subsequent 6 months), Interim follow-ups for Corox OTW
      Steroid LV lead related visits, and Out of Service visit. Data will be collected at each
      patient follow-up. The programmed pacing parameters, LV pacing impedance, and LV pacing
      threshold measurement at 0.5ms pulse width will be obtained. The programming parameters will
      be set to best suit each patient. If adequate system function, including effective CRT,
      cannot be obtained, the patient should not be selected for the registry.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Long-term Effectiveness of the COROX Over-the-wire (OTW) Steroid in Providing Biventricular Pacing</measure>
    <time_frame>All follow-ups for 3 years post implant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate threshold voltage of the COROX OTW Unipolar Lead.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of the COROX OTW Steroid LV Pacing Lead</measure>
    <time_frame>3 years post implant</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with LV lead related adverse events requiring additional invasive intervention to resolve.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Corox OTW Steroid Left Ventricular Lead</intervention_name>
    <description>This is a registry: no study required interventions necessary.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successfully implanted BIOTRONIK CRT-D system, including the Corox OTW Steroid LV
             Lead, from 1-30 days prior to enrollment

          -  Able to understand the nature of the registry and give informed consent

          -  Available for follow-up visits on a regular basis at the investigational site

          -  Age greater than or equal to 18 years

        Exclusion Criteria:

          -  Enrolled in another cardiovascular or pharmacological clinical investigation

          -  Planned cardiac surgical procedures or interventional measures within the next 6
             months

          -  Expected to receive a heart transplant within 6 months

          -  Life expectancy less than 6 months

          -  Presence of another life-threatening, underlying illness separate from their cardiac
             disorder

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katerina de Metz</last_name>
    <role>Study Director</role>
    <affiliation>Biotronik, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biotronik</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 27, 2012</lastchanged_date>
  <firstreceived_date>November 1, 2006</firstreceived_date>
  <firstreceived_results_date>February 22, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <keyword>Left Ventricular Lead</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Corox OTW Unipolar Lead</title>
          <description>Study Participants followed for three years post implant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study device explanted</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Corox OTW Unipolar Lead</title>
          <description>Study Participants followed for three years post implant.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="221"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="67.3" spread="11.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="168"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="221"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Long-term Effectiveness of the COROX Over-the-wire (OTW) Steroid in Providing Biventricular Pacing</title>
        <description>Evaluate threshold voltage of the COROX OTW Unipolar Lead.</description>
        <time_frame>All follow-ups for 3 years post implant</time_frame>
        <safety_issue>No</safety_issue>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Corox OTW Unipolar Lead</title>
            <description>Study Participants followed for three years post implant.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of LV Lead Threshold Tests analyzed</title>
            <units>LV Lead Threshold Tests</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1130"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Long-term Effectiveness of the COROX Over-the-wire (OTW) Steroid in Providing Biventricular Pacing</title>
            <description>Evaluate threshold voltage of the COROX OTW Unipolar Lead.</description>
            <units>Threshold Voltage</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="1.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety of the COROX OTW Steroid LV Pacing Lead</title>
        <description>Number of participants with LV lead related adverse events requiring additional invasive intervention to resolve.</description>
        <time_frame>3 years post implant</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All study participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Corox OTW Unipolar Lead</title>
            <description>Study Participants followed for three years post implant.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Safety of the COROX OTW Steroid LV Pacing Lead</title>
            <description>Number of participants with LV lead related adverse events requiring additional invasive intervention to resolve.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>High LV Lead Threshold</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>LV Lead Dislodgement</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Phrenic Nerve Stimulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Lead Integrity Comprimised noted at Device Change-Out</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Studies</name_or_title>
      <organization>Biotronik, Inc.</organization>
      <phone>503-451-8050</phone>
      <email>katerina.demetz@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
